Xoma, thrust into penny-stock territory after its lead drug failed in Phase III, isn't planning to shut its doors, instead pressing forward with the candidates it has left and promising to transform itself into a nimble biotech with a shot at survival.
After stoking investors' dreams of a turnaround, Xoma delivered another nightmare. The Berkeley, CA-based biotech reported early Wednesday that a Phase III study of gevokizumab in patients with Behçet's disease uveitis was a bust.
On Thursday, all of the content on Xoma's website was replaced by a single phrase.
After the markets closed on Tuesday, Xoma put out the word that its main pipeline asset, gevokizumab (Xoma 052) flunked a Phase II program for erosive osteoarthritis of the hand, ending any shot it had at a broad pivotal study in that indication.
Xoma has chosen a new home for a fixed-dose combination product for reducing blood pressure, transferring the asset to the startup Symplmed Pharmaceuticals in exchange for equity in the new company and up to double-digit royalties on potential U.S. sales.
Xoma says it hit its primary endpoint in a late-stage test of a blood pressure combo including Servier's perindopril, setting the stage for an NDA as the biotech goes hunting for a partner to market the therapy in the U.S.
CMC Biologics is a buying Xoma's large-scale manufacturing facility in the Bay Area, giving the company a regional foothold in one of biotech's hotbeds.
Tel Aviv-based Compugen has opened shop in a promised land of biotech, South San Francisco.
Xoma ($XOMA) has rung in 2012 with major cutbacks and organizational changes. The Berkeley, CA-based biotech company aims to axe 84 jobs or 34% of its work force by the end of the first quarter with
About 5 months after Xoma's ($XOMA) lead drug flamed out in a crucial mid-stage study, Steve Engle has resigned as CEO and chairman of the beleaguered biotech. The company quickly tapped board member